Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term open-label AMG 145 study in severe familial hypercholesterolemia
NL-OMON40135Phase 2Active, not recruiting
- Sponsor
- Amgen
- Start
- Jan 2014
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label trial of evolocumab in familial hypercholesterolemia (FH) (3 arms), sponsored by Amgen. Primary endpoint: Subject incidence of treatment emergent adverse events. Started Jan 2014; status: active, not recruiting.
02
Drugs
evolocumab
03
Conditions
familial hypercholesterolemia (FH)
Beyond the preview
Go deeper on NL-OMON40135.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON40135.